Morpholino antisense oligonucleotide treatment, designed to increase SMN protein levels, delivered at birth, specifically rescues a range of neuromuscular pathologies and significantly increases lifespan in SMA mouse models44. Here, SMN2 is linked to proximal spinal muscular atrophy.